ClinicalTrials.gg
RecruitingNCT07336732KANNON-5Updated Mar 20, 2026

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

A Phase 2 interventional study of PLB1004 in Non-Small-Cell Lung Cancer, sponsored by Avistone Biotechnology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Avistone Biotechnology Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 10 under way, 2 of them phase 3. andamertinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
10th of 11
40 · median 120
Started
2026
with 2 others
Phase 2
4 of 11
3 open now
Registered
10th of 11
by date
Lead sponsor
8 of 11
Avistone Biotechnology Co., Ltd.

Among the 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by planned enrollment, is one of 3 that started in 2026, is one of 4 in phase 2, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About andamertinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study is an open-label, randomized, multicenter phase II/III clinical trial designed to evaluate the efficacy, safety, and tolerability of Andamertinib with or without platinum-based chemothsrapy versus platinum-based chemotherapy in previously untreated participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR atypical mutations. The study comprises two stages: phase II (dose-exploration stage) and phase III (pivotal study stage)

Read the detailed description

This a three-stage study consist a Screening Phase (Day -28 to -1), a Treatment Phase (until treatment discontinuation), and a Follow-up Phase (including end of treatment visit (EOT),end of study visit(EOS), safety follow-up and survival follow-up).

03

Conditions studied

  • Non-Small-Cell Lung Cancer

Keywords

  • Non-Small-Cell Lung Cance
  • EGFR
  • PACC
  • L861Q
  • Lung Cancer
  • EGFR ex20ins
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years at the time of ICF signing.
  2. or cytologically confirmed, unresectable locally advanced (Stage IIIB or IIIC) or (Stage IV) non-squamous non-small cell lung cancer (NSCLC).
  3. Confirmed EGFR atypical mutation.
  4. No prior systemic therapy for locally advanced or metastatic NSCLC.
  5. At least one as defined by v1.1.
  6. PS ≤1.
  7. ≥12 weeks.
  8. Adequate organ function confirmed within 7 days prior to the first dose of study treatment
  9. Female participants must use adequate measures during study participation and for 90 days after the last dose of study treatment and must not be breastfeeding; female subjects not of must meet at least one of the following criteria at screening: status; Documentation of irreversible surgical sterilization.
  10. Non-sterilized males: Abstinence or contraception use; No sperm donation.
  11. Willing and able to provide signed ICF and to comply with all requirements and restrictions listed in the ICF and this study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Presence of specific genetic alterations for which approved targeted therapies are available.
  2. Recent participation (within 28 days) in another interventional clinical trial.
  3. Major surgery within 28 days prior to study entry or planned during the study period.
  4. Recent use of anti-tumor traditional proprietary medicine or local anti-tumor therapy.
  5. Need for specific concomitant medications (e.g., metformin) that cannot be paused during the study.
  6. History of another active within the past 5 years (except for specific cured cancers).
  7. Toxicities from prior therapy have not recovered to acceptable levels.
  8. Presence of symptomatic or uncontrolled , carcinomatous meningitis, or spinal cord compression.
  9. Symptomatic and uncontrolled third-space fluid accumulations (e.g., pleural effusion, ascites).
  10. Severe cardiovascular/cerebrovascular disease or risk factors (e.g., heart failure, history of myocardial infarction, , uncontrolled hypertension, etc.).
  11. History or presence of interstitial lung disease, or drug/radiation-related pneumonitis.
  12. Active or inflammatory diseases.
  13. Active, uncontrolled infection (including , , , syphilis, tuberculosis, etc.).
  14. Gastrointestinal disorders or surgery affecting drug ingestion or absorption.
  15. Active keratitis or ulcerative keratitis.
  16. History of to the study drug, its analogs, or chemotherapy drugs (pemetrexed/platinum agents).
  17. Recent administration (within 30 days) of a .
  18. Psychiatric disorders or substance abuse potentially affecting compliance.
  19. Any other condition deemed by the investigator as unsuitable for study participation.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Andamertinib with or without platinum-based chemothsrapy versus platinum-based chemotherapy

    PLB1004, oral, QD Platinum-based chemotherapy, injection, once every 21-day

    Drug: PLB1004

Interventions

  • Andamertinib with or without platinum-based chemothsrapy versus platinum-based chemotherapy

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).

    In phase II,Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to 3 years

  2. RP3D or recommended phase 3 treatment regimen

    In phase II, choose the RP3D per gained safety and efficacy data

    Time frame: Up to 3 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    To evaluate the Overall Response Rate (ORR) which is defined by investigator as the proportion of subjects with confirmed best overall response of complete response or partial response per RECIST v1.1

    Time frame: Up to 3 years

  2. Duration of Response(DOR)

    DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes frst

    Time frame: up to 3 years

  3. Disease Control Rate(DCR)

    The percentage of tumor patients achieving complete remission (CR), partial remission (PR), or stable disease (SD) following treatment, relative to the total number of evaluable subjects

    Time frame: up to 3 years

  4. Progression-Free Survival(PFS)

    PFS is defined as the time from the date the first dose until the date of objective disease progression or death by cause whichever comes first, based on investigator review according to RECIST v1.1

    Time frame: up to 3 years

  5. 6-month Progression-Free Survival Rate

    The proportion of subjects who did not experience disease progression or death within 6 months after receiving treatment.

    Time frame: up to 3 years

  6. 6-month Overall Survival Rate

    The proportion of subjects who did not experience death within 6 months after receiving treatment.

    Time frame: up to 3 years

  7. Assess the PK characteristics of Andamertinib

    Plasma concentration of Andamertinib

    Time frame: On cycle1of day 1and cycle3of day1, samples were collected within 2 hours prior to dosing and 4 hours post-dosing,On Day 1of Cycle 2, Cycle 5, Cycle 7, and all subsequent odd-numbered cycles collected within 2hours prior to dosing(each cycle is 21days)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 8 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Jan 13, 2026
StartActual
Mar 11, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Jan 2029
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07336732
Lead sponsor
Avistone Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Mar 11, 2026
Primary completion
Nov 2026 (estimated)
Completion
Jan 2029 (estimated)
Last update
Mar 20, 2026

Study contacts

Haimeng Li
Contact
lihaimeng@pearlbio.cn
+86 17610831060

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andamertinib

Start the discussion